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Abstract
Background
To investigate the role of microRNA (miR)-27a and miR-27b in adipogenesis in an in vitro
model of Graves’ orbitopathy (GO).
Methods
Orbital fat tissues were harvested from GO and non-GO participants for primary orbital fibro-
blast cultures. The expression levels of miR-27a and miR-27b between GO and non-GO
orbital fat tissues were compared. During adipogenesis of GO orbital fibroblasts, the expres-
sion levels of miR-27a and miR-27b were determined, and the effects of mimics of miR-27a
and miR-27b transfection on adipogenesis of GO orbital fibroblast were investigated.
Results
Real time-polymerase chain reaction showed significantly more decreases in miR-27a and
miR-27b levels in orbital fat tissues in GO participants than in non-GO participants (p <
0.05). The expression of both miR-27a and miR-27b was highest in orbital fibroblasts at day
0 and declined gradually after the induction of adipogenic differentiation. The expression lev-
els of PPARγ, CCAAT/enhancer binding protein (C/EBP)α and C/EBPβ were decreased
and Oil Red O-stained lipid droplets were lower in GO orbital fibroblasts transfected with
miR-27a and miR-27b mimics than in negative controls.
Conclusions
Our results indicated that miR-27a and miR-27b inhibited adipogenesis in orbital fibroblasts
from GO patients. Further studies are required to examine the potential of miR-27a and
miR-27b as targets for therapeutic strategies.
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Introduction
Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit [1–3]. The
clinical manifestations of GO reflect an increase in orbital volume, which might lead to propto-
sis, lid swelling, corneal exposure, diplopia, and compressive optic neuropathy [2–5]. Patients
with GO often suffer more from a disfiguring appearance than from their general condition
due to Graves’ disease.
Adipogenesis, the transition of activated orbital fibroblasts into adipocytes, can lead to
orbital proptosis in GO patients [6]. Proptosis, which is a leading cause of a disfiguring appear-
ance, is usually treated with orbital decompression [7–9]. Even though orbital decompression
is a well-established procedure for treating proptosis, the risks of postoperative complications
such as infection, bleeding, surgically-induced diplopia, or insufficient proptosis reduction still
exist [10–12]. There are therefore continuous efforts to identify methods to block the adipo-
genesis pathway as a new therapeutic option.
MicroRNAs (miRs) are non-coding single-stranded RNAs, comprised of approximately
22 nucleotides, which exert post-transcriptional effects on gene expression. There is grow-
ing evidence for the role of miRNAs in regulating the pathway of adipogenesis, and several
miRNAs have been found to be involved in adipogenesis [13]. MiR-27 is one of a number of
miRs implicated in regulating cholesterol and fatty acid metabolism [14]. The miR-27 gene
family has been shown to be downregulated during the differentiation of adipocytes. MiR-
27 inhibits adipocyte formation when overexpressed by blocking the expression of peroxi-
some-proliferator activated receptor-γ (PPARγ) and CCAAT/enhancer binding protein (C/
EBP)α [15].
In GO patients, adipogenesis is one of the most important pathomechanisms. We previ-
ously used microarray analysis to identify miRNAs involved in the pathogenesis of GO [16].
We found that 43 miRNAs, which included miR-27a, were dysregulated in orbital tissue from
GO patients when compared to healthy controls. Based on this background, in the present
study, we investigated the roles of miR-27a and miR-27b in adipogenesis using an in vitro
model of GO.
Materials and methods
Subjects and cell culture/adipogenesis protocols
Orbital adipose tissue was obtained from 13 GO patients and 8 non-GO subjects. All GO
patients satisfied the following conditions: 1) patients underwent orbital decompression for
proptosis correction; 2) euthyroid and inactive GO status at the time of surgery; and 3) patients
had not been treated with steroids or radiation therapy for at least 3 months. All control sub-
jects satisfied the following conditions: 1) age- and sex-matched to GO subjects; 2) without
thyroid or any other inflammatory diseases; and 3) control subjects underwent cosmetic upper
and lower blepharoplasty. Informed written consent was obtained from all participants, and
this study was approved by the Institutional Review Board of the Severance Hospital, Yonsei
University College of Medicine.
To compare the expression levels of miR-27a and miR-2b between GO and non-GO tissues,
orbital adipose/connective tissue explants from five GO patients and five control subjects were
used.
Orbital tissues were obtained from eight GO patients and three non-GO patients to per-
form cell-based experiments. Orbital fibroblast cell cultures were performed according to
methods described previously [16–19]. Procedures for adipogenesis and lipid droplet examina-
tion were performed as described previously [18,20].
Role of miR-27 in Graves’ orbitopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0221077 August 15, 2019 2 / 11
Competing interests: The authors have declared
that no competing interests exist.
All experiments were independently performed at least three times using at least three cell
cultures harvested from different individuals. The results are presented as the mean ± standard
deviation. Differences between groups were assessed by independent and paired t-tests. In all
analyses, p< 0.05 was assumed to indicate statistical significance.
Cell transfection with miR-27a and miR-27b mimics
Orbital fibroblasts were transfected with miR-27a and miR-27b mimics and each control
according to the manufacturer’s protocols. The miR-27a and miR-27b mimics were obtained
from Ambion/Applied Biosystems (Foster City, CA, USA). Cells were transfected with 50 nM
of miR-27a and miR-27b mimics using commercial reagents (Lipofectamine RNAiMAX; Life
Technologies, Carlsbad, CA, USA).
Quantitative real time-polymerase chain reaction (qRT-PCR) and western
blotting
qRT-PCR and western blotting were performed as described previously [16,19]. Briefly, for
qRT-PCR, total RNA was extracted from orbital fibroblasts according to the manufacturer’s
instructions. One μg of RNA was used to generate cDNA using a TaqMan miRs Reverse Tran-
scription Kit (Applied Biosystems). The cDNA was amplified using a thermocycler (ABI Ste-
pOnePlus RT-PCR; Applied Biosystems) with TaqMan universal PCR master mix (No
AmpErase UNG; Applied Biosystems). RNU6B expression was used for normalization. All
PCRs were performed in triplicate. The results are presented as relative fold changes of thresh-
old cycle (Ct) relative to the control group, determined using the 2−ΔΔCt method.
The effects of miR-27a and miR-27b mimics on PPARγ, C/EBPα, and C/EBPβ protein
release in GO orbital fibroblasts were analysed by western blotting. Transfected cells were
washed with ice-cold phosphate-buffered saline, and whole-cell lysates were obtained by incu-
bation on ice for 30 min in cell lysis buffer (20 mM HEPES, pH 7.2, 10% [v/v] glycerol, 10 mM
Na3VO4, 50 mM NaF, 1 mM phenylmethylsulphonyl fluoride, 0.1 mM dithiothreitol, 1 μg/mL
leupeptin, 1 μg/mL pepstatin, and 1% [v/v] Triton X-100). Reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Lysates were centrifuged at 12,000 × g for 10 min and
the cell homogenate fractions were stored at –70˚C until use.
Protein concentrations were determined by the Bradford assay. Equal amounts of protein
(50 μg) were boiled in sample buffer and resolved by 10% (w/v) sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis. Proteins were transferred onto polyvinylidene difluoride mem-
branes (Immobilon; Millipore, Bedford, MA, USA). The samples were incubated overnight
with primary antibodies (PPARγ, C/EBPα, and C/EBPβ) in Tris-buffered saline with Tween
20 (TBST), and washed three times with TBST. Immunoreactive bands were detected with
horseradish peroxidase-conjugated secondary antibody, signal developed using an enhanced
chemiluminescence kit (Amersham Pharmacia Biotechnology, Inc., Piscataway, NJ, USA) and
detected by exposure to X-ray film (Amersham Pharmacia Biotechnology, Inc.). The immuno-
reactive bands were quantified by densitometry and normalized relative to the β-actin levels in
the same sample.
Oil Red O staining
Orbital fibroblast cultures were plated in a one-well culture disc in Dulbecco’s Modified Eagle’s
Medium containing 10% foetal bovine serum, grown to confluence, and subjected to the dif-
ferentiation protocol. The cells were washed twice with 1× phosphate-buffered saline, fixed in
10% formalin overnight at room temperature, and rinsed in 60% isopropanol before staining
with filtered 0.21% Oil Red O in isopropanol-water for 1 h. Washed cells were exposed to
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Mayer’s haematoxylin solution (Sigma-Aldrich) for 5 min and rinsed with tap water before
being visualized and photographed at 200× using a BX60 light microscope (Olympus, Melville,
NY, USA).
To quantitatively evaluate of Oil Red O staining, cell-bound Oil Red O was solubilized with
100% isopropanol and the optical density of the solution was measured by a spectrophotome-
ter at 490 nm.
Results
Comparison of miR-27a and miR-27b expression in GO and non-GO
participants
The miR-27a and miR-27b expression levels were determined in orbital fat tissue obtained
from five GO and five non-GO participants using qRT-PCR. The expression levels of miR-27a
and miR-27b were significantly lower in orbital adipose tissues from GO than from non-GO
participants (p = 0.038 and p = 0.047, respectively; independent t-test; Fig 1).
MiR-27a and miR-27b expressions during adipogenesis in GO orbital
fibroblasts
Changes in expression levels of miR-27a and miR-27b in GO orbital fibroblasts during adipo-
genesis were investigated using qRT-PCR. MiR-27a expression was highest in orbital fibro-
blasts at day 0 and declined gradually after the induction of differentiation (day 4, p = 0.049;
day 7, p = 0.007; and day 10, p = 0.003; paired t-test compared to day 0) (Fig 2A). MiR-27b
expression was also highest in orbital fibroblasts at day 0 and declined gradually after the
induction of differentiation (day 4, p = 0.002; day 7, p< 0.001; and day 10, p< 0.001; paired t-
test compared to day 0) (Fig 2B).
Effects of miR-27a and miR-27b mimics on adipogenesis in GO and non-
GO orbital fibroblasts
The cellular miR-27a and miR-27b levels increased approximately 110,000- and 60,000-fold
following transfection of miR-27a and miR-27b mimics in GO orbital fibroblasts, respectively
(Fig 3A and 3B). The miR-27a and miR-27b levels also increased, by approximately 10,000-
and 3,000-fold following transfection of miR-27a and miR-27b mimics in non-GO orbital
fibroblasts, respectively (Fig 3C and 3D).
Fig 1. Comparison of microRNA-27 (miR-27)a and miR-27b expression in Graves’ orbitopathy (GO) and non-
GO control participants. (A) The expression levels of miR-27a and (B) miR-27b were significantly lower in orbital
adipose tissues from GO than from non-GO participants (�P<0.05).
https://doi.org/10.1371/journal.pone.0221077.g001
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To investigate changes in the mRNA levels of PPARγ, C/EBPα, and C/EBPβ, qRT-PCR was
performed in GO and non-GO orbital fibroblasts. The mRNA levels of PPARγ were signifi-
cantly decreased in GO orbital fibroblasts transfected with miR-27a and miR-27b mimics
(both, p< 0.001). The mRNA levels of C/EBPα were also significantly decreased in GO orbital
fibroblasts transfected with miR-27a and miR-27b mimics (p = 0.01 and p = 0.03, respectively).
The mRNA levels of C/EBPβ were decreased in GO orbital fibroblasts transfected with miR-
27a and miR-27b mimics (p = 0.15 and p = 0.001, respectively) (Fig 4A–4C).
We found similar trends in the mRNA levels of PPARγ, C/EBPα, and C/EBPβ in non-GO
orbital fibroblasts (Fig 4D–4F). The mRNA levels of PPARγ were significantly decreased in
GO orbital fibroblasts transfected with miR-27a and miR-27b mimics (p = 0.03 and p = 0.04,
respectively). The mRNA levels of C/EBPα were also significantly decreased in GO orbital
fibroblasts transfected with miR-27a and miR-27b mimics (both, p<0.01). The mRNA levels
of C/EBPβ were decreased in GO orbital fibroblasts transfected with miR-27a and miR-27b
mimics (p<0.01 and p = 0.08, respectively) (Fig 4D–4F).
To confirm these findings in terms of protein expression, western blot analysis was per-
formed; the results showed that the levels of adipogenic proteins including PPARγ, C/EBPα,
and C/EBPβ, were decreased in GO orbital fibroblasts that were transfected with miR-27a and
miR-27b mimics (Fig 5).
The numbers of Oil Red O-stained lipid droplets were reduced at day 10 in GO fibroblasts
that were transfected with miR-27a and miR-27b mimics (Fig 6). As results of quantification
of Oil Red O staining, the optical density of miR-27a and miR-27b mimics transfected cell
lysates showed significantly decreased absorbance at 490 nm compared to no transfected cell
lysates (p< 0.01, respectively; independent t-test; Fig 6).
Discussion
In the present study, we investigated the roles of miR-27a and miR-27b in adipogenesis in an
in vitro model of GO. The results showed a significant decrease in miR-27a and miR-27b levels
in orbital fat tissue from GO patients when compared to non-GO tissue. In GO orbital fibro-
blasts, the levels of miR-27a and miR-27b were gradually decreased upon adipogenic differen-
tiation. Furthermore, the adipogenesis-induced increases of PPARγ, C/EBPα, and C/EBPβ
proteins and mRNA were decreased in miR-27a and miR-27b mimic-transfected orbital fibro-
blasts. These results suggest that suppression of miR-27a and miR-27b might be involved in
adipocyte development by repressing the expression of PPARγ and C/EBP.
Dysregulation of miRs has been found to be involved in various human diseases, such as
cancer, inflammation, infection, and metabolic disorders [21]. Interest in adipogenesis has
been increasing due to its relevance to obesity. MiRs can accelerate as well as suppress
Fig 2. MicroRNA-27 (miR-27)a and miR-27b expression during adipogenesis in Graves’ orbitopathy orbital
fibroblasts. (A) The levels of miR-27a and (B) miR-27b were gradually decreased upon adipogenic differentiation.
(�P<0.05, ��P<0.01).
https://doi.org/10.1371/journal.pone.0221077.g002
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adipocyte differentiation [22]. For example, miR-143 is a miR that accelerates adipocyte differ-
entiation [23,24]. Esau et al. [24] found that miR-143 levels increased in differentiating adipo-
cytes, and inhibition of miR-143 inhibited adipocyte differentiation. In contrast, miR-27a and
miR-27b impair adipocyte differentiation by targeting PPARγ [25,26]. Kim et al. [26] reported
similar findings in studies using mice 3T3-L1 cells, and Karbiener et al. [25] reported similar
Fig 3. Cellular microRNA-27 (miR-27)a and miR-27b levels. (A) The levels of miR-27a and (B) miR-27b increased following transfection of miR-27a and miR-27b
mimics in GO orbital fibroblasts. (C) The levels of miR-27a and (D) miR-27b increased following transfection of miR-27a and miR-27b mimics in non-GO orbital
fibroblasts. NC, negative control.
https://doi.org/10.1371/journal.pone.0221077.g003
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results using human multipotent adipose-derived stem cells. The results in the present study
were consistent with these previous reports. The expression levels of miRs that suppress adipo-
cyte differentiation have been shown to be lower in differentiating adipocytes [15,25,26]. Like-
wise, the levels of miR-27a and miR-27b decreased upon adipogenesis in orbital fibroblasts
from GO patients. These results suggest that miR-27a and miR-27b downregulation is neces-
sary for adipocyte hypertrophy.
Because miRs play diverse and important roles in almost all aspects of cell physiology, it can
be complex to apply miRs to clinical uses. Nevertheless, there have been studies on the use of
miRs for clinical purposes. Recently, Mu et al. [27] suggested a new therapeutic strategy of the
combined use of miRNA and anticancer drugs to increase drug responses in liver and kidney
cancer patients. Liver and kidney cancers are notorious for drug resistance, and the authors
found that miR-27b is sometimes deleted in liver and kidney cancers. Notably, the authors
reported that miR-27b promoted drug responses in liver and kidney cancer patients in an in
vivo study [27]. MiRs including miR-27a and miR-27b may provide therapeutic targets to treat
fat metabolism disorders by controlling fat cell development.
In the present study, we used orbital fat tissues and primary cultures of orbital fibroblasts
harvested from GO and non-GO participants. We compared the expression levels of miR-27a
Fig 4. Effects of microRNA-27 (miR-27)a and miR-27b mimics on peroxisome-proliferator activated receptor-γ (PPARγ), CCAAT/enhancer binding protein (C/
EBP)α, and C/EBPβ mRNA expression in Graves’ orbitopathy (GO) and non-GO orbital fibroblasts. (A, B) mRNA levels of PPARγ and C/EBPα were increased on
day 10 of adipogenesis, and significantly decreased in GO orbital fibroblasts transfected with miR-27a and miR-27b mimics. (C) mRNA levels of C/EBPβ were
significantly decreased in GO orbital fibroblast transfected with miR-27b mimics. The mRNA levels of C/EBPβ were decreased in GO orbital fibroblasts transfected with
miR-27a mimics, albeit not significantly. (D, E) The mRNA levels of PPARγ and C/EBPα, were increased on 10 day of adipogenesis, and significantly decreased in
orbital fibroblasts transfected with miR-27a and miR-27b mimics. (F) The mRNA levels of C/EBPβ were significantly decreased in orbital fibroblasts transfected with
miR-27a mimics. The mRNA levels of C/EBPβ were decreased in GO orbital fibroblast transfected with miR-27b mimics, although not significantly. NC, negative
control. (�P<0.05, ��P<0.01).
https://doi.org/10.1371/journal.pone.0221077.g004
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Fig 5. Effects of microRNA-27 (miR-27)a and miR-27b mimics on peroxisome-proliferator activated receptor-γ (PPARγ), CCAAT/enhancer binding
protein (C/EBP)α, and C/EBPβ protein release in Graves’ orbitopathy orbital fibroblasts. (A) Representative photo of western blot analysis. (B) Protein levels
of C/EBPα, (C) C/EBPβ and (D) PPARγ were increased on 10 day of adipogenesis and significantly decreased in orbital fibroblasts that were transfected with
miR-27a and miR-27b mimics (�P<0.05). NC, negative control.
https://doi.org/10.1371/journal.pone.0221077.g005
Fig 6. Oil red O staining after adipogenesis on day 10. (A) No transfection, (B) negative control mimics, (C) microRNA-27(miR-27)a-transfected orbital fibroblasts,
(D) miR-27b-transfected orbital fibroblasts. Note that the levels of Oil Red O stained lipid droplets were reduced on day 10 in orbital fibroblasts that were transfected
with the miR-27a or miR-27b mimic. (E) The optical density of miR-27a and miR-27b mimics transfected cell lysates showed significantly decreased absorbance at 490
nm (�P<0.01). NC, negative control.
https://doi.org/10.1371/journal.pone.0221077.g006
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and miR-27b between GO and non-GO orbital fat tissues and found that the levels of both
were significantly lower in GO fat tissue than in non-GO fat tissue. We also confirmed that
miR-27a and miR-27b inhibited adipogenic differentiation in orbital fibroblasts from patients
with GO. However, further studies using an experimental animal model of GO [28] are
required to examine the potential of miR-27a and miR-27b as targets in GO treatments, espe-
cially for patients with disfiguring proptosis.
PPARγ and members of the C/EBP family are key players in adipocyte differentiation.
Almost all genes involved in lipid metabolism have PPARγ:retinoid X receptor target sites
[29,30]. In the present study, we found that the protein and mRNA expression levels of
PPARγ, C/EBPα, and C/EBPβ were decreased in orbital fibroblasts that were transfected with
either miR-27a or miR-27b mimics. However, the extents of the decreases were slightly differ-
ent between miR-27a and miR-27b transfected cells. The miR-27a mimic more strongly inhib-
ited PPARγ protein and mRNA expression than the miR-27b mimic in orbital fibroblasts.
These findings were also observed in Oil Red O-staining adipocytes.
In conclusion, we demonstrated that miR-27a and miR-27b inhibited adipogenic differenti-
ation in orbital fibroblast from patients with GO. Our data further support a novel negative
regulatory mechanism of PPARγ-mediated adipogenesis by miR-27a and miR-27b, and sug-
gest that miR-27a and miR-27b represent potential therapeutic targets for proptosis due to
GO.
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